BioPharma Drug Approval
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related...
August 07, 2023 | News
Orphan Drug Designation is a significant recognition bestowed by the FDA to the drugs used in the treatment of rare diseases. This designation intends to e...
August 03, 2023 | News
The Phase I MAD study is a randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics ...
August 02, 2023 | News
This is a first-in-human, single-arm, multicenter, open-label, dose-escalation and expansion clinical study, and plans to enroll patients with relapsed/ref...
August 01, 2023 | News
This study aims to evaluate the safety, tolerability, and pharmacokinetics of TST002(Blosozumab) after single and multiple intravenous administrations in p...
July 31, 2023 | News
B7-H3 is a member of the B7 ligand family and is overexpressed in most cancer types but expressed at a low level in normal tissues. In malignant tissues, B...
July 24, 2023 | News
Striving to further expand its territory to Africa and the Middle East from Southeast Asia and Latin America "Will cr...
July 24, 2023 | News
SNB-101 showed excellent efficacy in animal small cell lung cancer models, and based on this, it has been designated as an orphan drug by the US FDA after ...
July 21, 2023 | News
9MW2921 is a next generation antibody-drug conjugate (ADC) developed by Mabwell based on IDDC™ (Interchain-Disulfide Drug Conjugate) platef...
July 19, 2023 | News
XPOVIO® has received regulatory approvals in 41 countries and regions including the United States, Israel, the United Kingdo...
July 17, 2023 | News
Fast Track Designation (FTD) aims to facilitate the development of drugs targeting severe or life-threatening diseases that have the potential to a...
July 12, 2023 | News
80Bio, Inc. a clinical stage biotechnology company focused on the development of precision oncology medicines, today announced that the U.S. Food and Drug ...
July 10, 2023 | News
To initiate TranStar 301 global Phase III pivotal trial of Osemitamab (TST001) in combination with Nivolumab and chemotherapy for the first-line treatment ...
July 10, 2023 | News
The study is a prospective, self-controlled, multicenter Phase Ⅲ trial aimed at investigating the additional detection rate and safety of Hexvix®&nbs...
July 10, 2023 | News
Most Read
Bio Jobs
News
Editor Picks